Portal de investigação
Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Paraskevas, KI
- Gloviczki, P
- Antignani, PL
- Comerota, AJ
- Dardik, A
- Davies, AH
- Eckstein, HH
- Faggioli, G
- Fernandes, JFE
- Fraedrich, G
- Geroulakos, G
- Golledge, J
- Gupta, A
- Gurevich, VS
- Jawien, A
- Jezovnik, MK
- Kakkos, SK
- Knoflach, M
- Lanza, G
- Liapis, CD
- Loftus, IM
- Nicolaides, AN
- Pini, R
- Poredos, P
- Proczka, RM
- Ricco, JB
- Rundek, T
- Saba, L
- Schlachetzki, F
- Silvestrini, M
- Spinelli, F
- Stilo, F
- Suri, JS
- Svetlikov, A
- Zeebregts, CJ
- Chaturvedi, S
- Veith, FJ
- Mikhailidis, DP
Unidades de investigação
Abstract
International guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with statins or non-statin medications for Asx/SCS patients. The cerebrovascular and CV beneficial effects associated with statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and other non-statin lipid-lowering agents (e.g. fibrates, ezetimibe) are reviewed. The use of statins and PCSK9 inhibitors is associated with several beneficial effects for Asx/SCS patients, including carotid plaque stabilization and reduction of stroke rates. Ezetimibe and fibrates are associated with smaller reductions in stroke rates. The side-effects resulting from statin and PCSK9 inhibitor use are also highlighted. The benefits associated with lowering LDL-C with statins or non-statin lipid lowering agents (e.g. PCSK9 inhibi-tors) outweigh the risks and potential side-effects. Irrespective of their LDL-C levels, all Asx/SCS patients should receive high-dose statin treatment +/- ezetimibe or PCSK9 inhibitors for reduction not only of LDL-C levels, but also of stroke, cardiovascular mortality and coronary event rates.(c) 2022 Elsevier Inc. All rights reserved.
Copyright © 2022 Elsevier Inc. All rights reserved.
Dados da publicação
- ISSN/ISSNe:
- 1873-1740, 0033-0620
- Tipo:
- Review
- Páginas:
- 41-47
- PubMed:
- 35605696
- Link para outro recurso:
- www.scopus.com
Progress in Cardiovascular Diseases W.B. Saunders Ltd
Citações Recebidas na Web of Science: 9
Citações Recebidas na Scopus: 18
Documentos
- Não há documentos
Filiações
Keywords
- Carotid artery stenosis; Best medical treatment; Carotid endarterectomy; Carotid artery stenting; Statins; Proprotein convertase subtilisin; kexin type 9 (PCSK9) inhibitors
Projetos associados
Endovascular Treatment of Aortic Arch Aneurysms
Investigador Principal: Armando Amilcar Pires Mansilha Rodrigues de Almeida
Estudo Clínico Académico (Aneurysms) . 2020
The role of infrared thermography in predicting diabetic foot outcomes
Investigador Principal: Armando Amilcar Pires Mansilha Rodrigues de Almeida
Estudo Clínico Académico (diabetic foot) . 2021
Endovascular solutions for type IA endoleak after endovascular aneurysm repair
Investigador Principal: Armando Amilcar Pires Mansilha Rodrigues de Almeida
Estudo Clínico Académico . 2021
Intermittent Claudication: Importance of Supervised Exercise Programme
Investigador Principal: Armando Amilcar Pires Mansilha Rodrigues de Almeida
Estudo Clínico Académico . 2021
